CLINICAL TRIALS PROFILE FOR IMG-7289
✉ Email this page to a colleague
Clinical Trials for IMG-7289
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT02842827 ↗ | IMG-7289, With and Without ATRA, in Patients With Advanced Myeloid Malignancies | Completed | Imago BioSciences,Inc. | Phase 1 | This is a Phase 1 open label study of the dose and duration of an orally administered LSD1 inhibitor, IMG-7289, in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Some participants may also receive all-trans retinoic acid (ATRA; also known as tretinoin and Vesanoid®) in combination with IMG-7289. This study investigates the following: - The safety and tolerability of IMG-7289, with and without ATRA - The pharmacodynamic effect of different IMG-7289 doses and treatment durations, as well as IMG-7289 administered in combination with ATRA - The pharmacokinetics of IMG-2789, with and without ATRA |
NCT03136185 ↗ | IMG-7289 in Patients With Myelofibrosis | Active, not recruiting | Imago BioSciences,Inc. | Phase 2 | This is a Phase 2b open label study of an orally administered LSD1 inhibitor, IMG-7289, in patients with myelofibrosis. This study investigates the following: - The safety and tolerability of IMG-7289 - The pharmacokinetics of IMG-7289 (performed in Phase 1/2a only) - The pharmacodynamic effect of IMG-7289 |
NCT04081220 ↗ | Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2 | Recruiting | Imago BioSciences,Inc. | Phase 2 | This is a single-center, open-label investigator-initiated trial evaluating the effects of IMG-7289 administered orally once daily in patients with essential thrombocythemia. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for IMG-7289
Condition Name
Clinical Trial Locations for IMG-7289
Trials by Country
Clinical Trial Progress for IMG-7289
Clinical Trial Phase
Clinical Trial Sponsors for IMG-7289
Sponsor Name